PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being activel...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Jong-Mu Sun [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
Carcinoma, non-small-cell lung |
|---|
| Übergeordnetes Werk: |
In: Precision and Future Medicine - Sungkyunkwan University School of Medi, 2019, 1(2017), 1, Seite 3-9 |
|---|---|
| Übergeordnetes Werk: |
volume:1 ; year:2017 ; number:1 ; pages:3-9 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.23838/pfm.2017.00066 |
|---|
| Katalog-ID: |
DOAJ027220850 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ027220850 | ||
| 003 | DE-627 | ||
| 005 | 20230307112208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23838/pfm.2017.00066 |2 doi | |
| 035 | |a (DE-627)DOAJ027220850 | ||
| 035 | |a (DE-599)DOAJ32003cae037f4d05a46152bee05a6f77 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Jong-Mu Sun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. | ||
| 650 | 4 | |a Carcinoma, non-small-cell lung | |
| 650 | 4 | |a First-line therapy | |
| 650 | 4 | |a Programmed death 1 inhibitor | |
| 650 | 4 | |a Programmed death ligand 1 expression | |
| 650 | 4 | |a Programmed death ligand 1 inhibitor | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 773 | 0 | 8 | |i In |t Precision and Future Medicine |d Sungkyunkwan University School of Medi, 2019 |g 1(2017), 1, Seite 3-9 |w (DE-627)1760594881 |x 25087959 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2017 |g number:1 |g pages:3-9 |
| 856 | 4 | 0 | |u https://doi.org/10.23838/pfm.2017.00066 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/32003cae037f4d05a46152bee05a6f77 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2508-7940 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2508-7959 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2017 |e 1 |h 3-9 | ||
| author_variant |
j m s jms |
|---|---|
| matchkey_str |
article:25087959:2017----::dplihbtrhrptastoigrmscnlntaislntea |
| hierarchy_sort_str |
2017 |
| publishDate |
2017 |
| allfields |
10.23838/pfm.2017.00066 doi (DE-627)DOAJ027220850 (DE-599)DOAJ32003cae037f4d05a46152bee05a6f77 DE-627 ger DE-627 rakwb eng Jong-Mu Sun verfasserin aut PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor Medicine R In Precision and Future Medicine Sungkyunkwan University School of Medi, 2019 1(2017), 1, Seite 3-9 (DE-627)1760594881 25087959 nnns volume:1 year:2017 number:1 pages:3-9 https://doi.org/10.23838/pfm.2017.00066 kostenfrei https://doaj.org/article/32003cae037f4d05a46152bee05a6f77 kostenfrei http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf kostenfrei https://doaj.org/toc/2508-7940 Journal toc kostenfrei https://doaj.org/toc/2508-7959 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2017 1 3-9 |
| spelling |
10.23838/pfm.2017.00066 doi (DE-627)DOAJ027220850 (DE-599)DOAJ32003cae037f4d05a46152bee05a6f77 DE-627 ger DE-627 rakwb eng Jong-Mu Sun verfasserin aut PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor Medicine R In Precision and Future Medicine Sungkyunkwan University School of Medi, 2019 1(2017), 1, Seite 3-9 (DE-627)1760594881 25087959 nnns volume:1 year:2017 number:1 pages:3-9 https://doi.org/10.23838/pfm.2017.00066 kostenfrei https://doaj.org/article/32003cae037f4d05a46152bee05a6f77 kostenfrei http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf kostenfrei https://doaj.org/toc/2508-7940 Journal toc kostenfrei https://doaj.org/toc/2508-7959 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2017 1 3-9 |
| allfields_unstemmed |
10.23838/pfm.2017.00066 doi (DE-627)DOAJ027220850 (DE-599)DOAJ32003cae037f4d05a46152bee05a6f77 DE-627 ger DE-627 rakwb eng Jong-Mu Sun verfasserin aut PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor Medicine R In Precision and Future Medicine Sungkyunkwan University School of Medi, 2019 1(2017), 1, Seite 3-9 (DE-627)1760594881 25087959 nnns volume:1 year:2017 number:1 pages:3-9 https://doi.org/10.23838/pfm.2017.00066 kostenfrei https://doaj.org/article/32003cae037f4d05a46152bee05a6f77 kostenfrei http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf kostenfrei https://doaj.org/toc/2508-7940 Journal toc kostenfrei https://doaj.org/toc/2508-7959 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2017 1 3-9 |
| allfieldsGer |
10.23838/pfm.2017.00066 doi (DE-627)DOAJ027220850 (DE-599)DOAJ32003cae037f4d05a46152bee05a6f77 DE-627 ger DE-627 rakwb eng Jong-Mu Sun verfasserin aut PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor Medicine R In Precision and Future Medicine Sungkyunkwan University School of Medi, 2019 1(2017), 1, Seite 3-9 (DE-627)1760594881 25087959 nnns volume:1 year:2017 number:1 pages:3-9 https://doi.org/10.23838/pfm.2017.00066 kostenfrei https://doaj.org/article/32003cae037f4d05a46152bee05a6f77 kostenfrei http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf kostenfrei https://doaj.org/toc/2508-7940 Journal toc kostenfrei https://doaj.org/toc/2508-7959 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2017 1 3-9 |
| allfieldsSound |
10.23838/pfm.2017.00066 doi (DE-627)DOAJ027220850 (DE-599)DOAJ32003cae037f4d05a46152bee05a6f77 DE-627 ger DE-627 rakwb eng Jong-Mu Sun verfasserin aut PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor Medicine R In Precision and Future Medicine Sungkyunkwan University School of Medi, 2019 1(2017), 1, Seite 3-9 (DE-627)1760594881 25087959 nnns volume:1 year:2017 number:1 pages:3-9 https://doi.org/10.23838/pfm.2017.00066 kostenfrei https://doaj.org/article/32003cae037f4d05a46152bee05a6f77 kostenfrei http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf kostenfrei https://doaj.org/toc/2508-7940 Journal toc kostenfrei https://doaj.org/toc/2508-7959 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 1 2017 1 3-9 |
| language |
English |
| source |
In Precision and Future Medicine 1(2017), 1, Seite 3-9 volume:1 year:2017 number:1 pages:3-9 |
| sourceStr |
In Precision and Future Medicine 1(2017), 1, Seite 3-9 volume:1 year:2017 number:1 pages:3-9 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Precision and Future Medicine |
| authorswithroles_txt_mv |
Jong-Mu Sun @@aut@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
1760594881 |
| id |
DOAJ027220850 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027220850</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307112208.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.23838/pfm.2017.00066</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027220850</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ32003cae037f4d05a46152bee05a6f77</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jong-Mu Sun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Carcinoma, non-small-cell lung</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">First-line therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Programmed death 1 inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Programmed death ligand 1 expression</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Programmed death ligand 1 inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Precision and Future Medicine</subfield><subfield code="d">Sungkyunkwan University School of Medi, 2019</subfield><subfield code="g">1(2017), 1, Seite 3-9</subfield><subfield code="w">(DE-627)1760594881</subfield><subfield code="x">25087959</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:3-9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.23838/pfm.2017.00066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/32003cae037f4d05a46152bee05a6f77</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2508-7940</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2508-7959</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">3-9</subfield></datafield></record></collection>
|
| author |
Jong-Mu Sun |
| spellingShingle |
Jong-Mu Sun misc Carcinoma, non-small-cell lung misc First-line therapy misc Programmed death 1 inhibitor misc Programmed death ligand 1 expression misc Programmed death ligand 1 inhibitor misc Medicine misc R PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| authorStr |
Jong-Mu Sun |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760594881 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
25087959 |
| topic_title |
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer Carcinoma, non-small-cell lung First-line therapy Programmed death 1 inhibitor Programmed death ligand 1 expression Programmed death ligand 1 inhibitor |
| topic |
misc Carcinoma, non-small-cell lung misc First-line therapy misc Programmed death 1 inhibitor misc Programmed death ligand 1 expression misc Programmed death ligand 1 inhibitor misc Medicine misc R |
| topic_unstemmed |
misc Carcinoma, non-small-cell lung misc First-line therapy misc Programmed death 1 inhibitor misc Programmed death ligand 1 expression misc Programmed death ligand 1 inhibitor misc Medicine misc R |
| topic_browse |
misc Carcinoma, non-small-cell lung misc First-line therapy misc Programmed death 1 inhibitor misc Programmed death ligand 1 expression misc Programmed death ligand 1 inhibitor misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Precision and Future Medicine |
| hierarchy_parent_id |
1760594881 |
| hierarchy_top_title |
Precision and Future Medicine |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760594881 |
| title |
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| ctrlnum |
(DE-627)DOAJ027220850 (DE-599)DOAJ32003cae037f4d05a46152bee05a6f77 |
| title_full |
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| author_sort |
Jong-Mu Sun |
| journal |
Precision and Future Medicine |
| journalStr |
Precision and Future Medicine |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
txt |
| container_start_page |
3 |
| author_browse |
Jong-Mu Sun |
| container_volume |
1 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Jong-Mu Sun |
| doi_str_mv |
10.23838/pfm.2017.00066 |
| title_sort |
pd-1/pd-l1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| title_auth |
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| abstract |
Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. |
| abstractGer |
Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. |
| abstract_unstemmed |
Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
1 |
| title_short |
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer |
| url |
https://doi.org/10.23838/pfm.2017.00066 https://doaj.org/article/32003cae037f4d05a46152bee05a6f77 http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf https://doaj.org/toc/2508-7940 https://doaj.org/toc/2508-7959 |
| remote_bool |
true |
| ppnlink |
1760594881 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.23838/pfm.2017.00066 |
| up_date |
2024-07-04T00:51:32.572Z |
| _version_ |
1803607649892171776 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ027220850</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307112208.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.23838/pfm.2017.00066</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ027220850</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ32003cae037f4d05a46152bee05a6f77</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jong-Mu Sun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Recently, monoclonal antibodies targeting the programmed death 1 (PD-1)/PD ligand 1 (PD-L1) pathway have dramatically changed the treatment paradigm for non-small cell lung cancer (NSCLC). Several PD-1/PD-L1 inhibitors have been validated as second-line therapies for NSCLC, and are now being actively investigated as first-line therapies. In this paper, current data and future strategies for their use in first-line therapy are reviewed. There are five PD-1/PD-L1 inhibitors in development for NSCLC. Among them, three drugs (nivolumab, pembrolizumab, and atezolizumab) have been approved as second-line therapies for NSCLC in the United States. As a first-line therapy, pembrolizumab successfully showed superiority over platinum-based doublet chemotherapy in a strongly PD-L1-positive NSCLC group, while nivolumab failed to show efficacy as a first-line therapy. Currently, five PD-1/PD-L1 inhibitors are being tested as a first-line therapy for NSCLC in more than 10 phase III studies, with various study designs. Although it is not yet clear whether PD-1/PD-L1 inhibitors should be used as a monotherapy or in combination according to PD-L1 expression in first-line therapies, these promising drugs may play an important role in clinical practice as a first-line therapy for NSCLC in the near future.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Carcinoma, non-small-cell lung</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">First-line therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Programmed death 1 inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Programmed death ligand 1 expression</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Programmed death ligand 1 inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Precision and Future Medicine</subfield><subfield code="d">Sungkyunkwan University School of Medi, 2019</subfield><subfield code="g">1(2017), 1, Seite 3-9</subfield><subfield code="w">(DE-627)1760594881</subfield><subfield code="x">25087959</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:3-9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.23838/pfm.2017.00066</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/32003cae037f4d05a46152bee05a6f77</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.pfmjournal.org/upload/pdf/pfm-2017-00066.pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2508-7940</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2508-7959</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">3-9</subfield></datafield></record></collection>
|
| score |
7.4013557 |